Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 89 of the 95 references it cites were found in a registry or an index; 36 of the 76 sources its claims cite were checked for support.

Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

Open access

Abstract

Context: Polycystic ovary syndrome (PCOS) affects more than 1 in 10 women. Objective: As part of the 2023 International PCOS Guidelines update, comparisons between combined oral contraceptive pills (COCP), metformin, and combination treatment were evaluated. Data Sources: Ovid Medline, Embase, PsycINFO, All EBM, and CINAHL were searched. Study Selection: Women with PCOS included in randomized controlled trials (RCTs). Data Extraction: We calculated mean differences and 95% CIs regarding anthropometrics, metabolic, and hyperandrogenic outcomes. Meta-analyses and quality assessment using GRADE were performed. Data Synthesis: The search identified 1660 publications; 36 RCTs were included. For hirsutism, no differences were seen when comparing metformin vs COCP, nor when comparing COCP vs combination treatment with metformin and COCP. Metformin was inferior on free androgen index (FAI) (7.08; 95% CI 4.81, 9.36), sex hormone binding globulin (SHBG) (−118.61 nmol/L; 95% CI −174.46, −62.75) and testosterone (0.48 nmol/L; 95% CI 0.32, 0.64) compared with COCP. COCP was inferior for FAI (0.58; 95% CI 0.36, 0.80) and SHBG (−16.61 nmol/L; 95% CI −28.51, −4.71) compared with combination treatment, whereas testosterone did not differ. Metformin lowered insulin (−27.12 pmol/L; 95% CI −40.65, −13.59) and triglycerides (−0.15 mmol/L; 95% CI −0.29, −0.01) compared with COCP. COCP was inferior for insulin (17.03 pmol/L; 95% CI 7.79, 26.26) and insulin resistance (0.44; 95% CI 0.17, 0.70) compared with combination treatment. Conclusions: The choice of metformin or COCP treatment should be based on symptoms, noting some biochemical benefits from combination treatment targeting both major endocrine disturbances seen in PCOS (hyperinsulinemia and hyperandrogenism).

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of 36 RCTs compared metformin, combined oral contraceptive pills (COCP), and combination treatment in women with PCOS. COCP was superior for cycle regularity and some androgen outcomes, metformin was superior for metabolic outcomes, and combination treatment improved biochemical hyperandrogenism and insulin measures over COCP alone.

Key findings

  • Among 36 RCTs, metformin was inferior to COCP for free androgen index (MD 7.08; 95% CI 4.81–9.36), SHBG (MD −118.61 nmol/L; 95% CI −174.46 to −62.75), and total testosterone (MD 0.48 nmol/L; 95% CI 0.32–0.64), with no overall hirsutism difference; metformin was superior for fasting insulin (MD −27.12 pmol/L; 95% CI −40.65 to −13.59), triglycerides (MD −0.15 mmol/L; 95% CI −0.29 to −0.01), total cholesterol (MD −0.40 mmol/L; 95% CI −0.66 to −0.14), and CRP (MD −11.31 nmol/L; 95% CI −19.78 to −2.85).
  • Metformin was inferior to COCP for restoring regular menses (OR 0.17; 95% CI 0.05–0.57).
  • COCP alone was inferior to COCP plus metformin for FAI (MD 0.58; 95% CI 0.36–0.80), SHBG (MD −16.61 nmol/L; 95% CI −28.51 to −4.71), DHEAS (MD 0.93 μmol/L; 95% CI 0.54–1.31), androstenedione (MD 1.37 nmol/L; 95% CI 0.14–2.60), fasting insulin (MD 17.03 pmol/L; 95% CI 7.79–26.26), HOMA-IR (MD 0.44; 95% CI 0.17–0.70), and CRP (MD 1.94 nmol/L; 95% CI 0.05–3.84), with no difference in hirsutism or total/free testosterone.
  • Metformin alone was inferior to combination treatment for DHEAS (MD 82.38 μmol/L; 95% CI 15.43–149.36) and total testosterone (MD 0.64 nmol/L; 95% CI 0.26–1.02), but had marginally lower fasting glucose (MD −0.33 mmol/L; 95% CI −0.64 to −0.01) and CRP (MD −4.08 nmol/L; 95% CI −6.01 to −2.16).

Methods

  • Systematic review and meta-analysis conducted for the 2023 International PCOS Guidelines update, following PRISMA and registered in PROSPERO (CRD42022345640). Searches of Ovid Medline, Embase, PsycINFO, All EBM, and CINAHL covered 2017 to July 7, 2022, plus re-evaluation of the previous 1946–2017 search; 1660 publications were identified, 450 full texts reviewed, plus 176 from the previous search, yielding 36 RCTs in 46 publications.
  • Included RCTs of women with PCOS (Rotterdam, NIH, or AES criteria) comparing metformin, COCP, or COCP plus metformin; outcomes included anthropometric, metabolic, androgenicity, psychological, and adverse-event measures.
  • Random-effects meta-analyses used Review Manager 5.4.1, calculating mean differences and 95% CIs for continuous outcomes and odds ratios and 95% CIs for dichotomous outcomes; risk of bias was assessed with RoB2 and certainty with GRADE, with subgroup analyses by BMI, age, and COCP type.

Limitations

  • Paper-stated limitations: many included studies had high risk of bias (20 high, 14 some concerns, 2 low), often due to poorly described randomization or lack of blinding; certainty of evidence was affected by inconsistency of effect sizes and small sample sizes; several studies did not provide BMI data; adverse effects could not be meta-analyzed due to lack of systematic reporting; health-related quality of life could not be meta-analyzed; research gaps include lack of larger studies in adolescents and of metformin versus combination treatment.
  • Evident from the text: most GRADE certainty ratings were low or very low, and several comparisons relied on few studies or participants, limiting precision and generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1210/clinem/dgad465

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Included studies are shown in the PRISMA flowchart. The search was performed for 3 medical treatments (combined oral contraceptive pills [COCP], metformin, and anti-androgens) as part of the update of the PCOS guidelines. Results comparing COCP, metformin, and combined COCP and metformin were included in this systematic review.
Figure 1. Included studies are shown in the PRISMA flowchart. The search was performed for 3 medical treatments (combined oral contraceptive pills [COCP], metformin, and anti-androgens) as part of the update of the PCOS guidelines. Results comparing COCP, metformin, and combined COCP and metformin were included in this systematic review.CC BY-NC-ND · PubMed Central
Figure 2. Risk of bias assessments of the included studies.
Figure 2. Risk of bias assessments of the included studies.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

24 Valid · 4 Not valid · 29 Not checked · 105 Own results and interpretations

111 more claims · 8 with their cited sources checked

Create a free account to see all 162 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 37
  • It may state two separate claims as one. 13
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 95 references

Research works printed but not linked: 2

  1. Schünemann, GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations
  2. Aghamohammadzadeh, 2010, Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome, Pak J Med Sci, 2, 347

Cited by

See all 78

Metadata

Authors
Melin, J., Forslund, M., Alesi, S., Piltonen, T., Romualdi, D., Spritzer, P. M., Tay, C. T., Pena, A., Witchel, S. F., Mousa, A., & Teede, H.
Affiliations
  • University of Helsinki (FI)
  • Monash University (AU)
  • Oulu University Hospital (FI)
  • Agostino Gemelli University Polyclinic (IT)
  • Universidade Federal do Rio Grande do Sul (BR)
  • Discipline of Paediatrics, The University of Adelaide and Robinson Research Institute , Adelaide, South Australia 5005 , Australia
  • Children's Hospital of Pittsburgh (US)
  • Monash Medical Centre (AU)
Corresponding author
Melin, Johanna
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2023-08-09
Volume
109
Issue
2
Pages
e817-e836
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4385679942
Cited by
78
References
95
Citations by year
2026: 29 · 2025: 31 · 2024: 17 · 2023: 1
FWCI
3.13
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc-nd)
  • Työväentutkimus Vuosikirja (submittedVersion)
Funders
  • The Medical Society of Finland
  • Orion Research foundation
  • Iris foundation
  • Hjalmar Svensson Foundation
  • National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
Keywords
polycystic ovary syndrome, metformin, combined oral contraceptives, combination therapy, hirsutism, free androgen index, sex hormone-binding globulin, testosterone, insulin, insulin resistance, triglycerides, hyperandrogenism, ovulation induction, pregnancy outcomes, cardiovascular risk, quality of life
MeSH terms
Contraceptives, Oral, Combined, Female, Humans, Hypoglycemic Agents, Metformin, Polycystic Ovary Syndrome, Testosterone, Insulins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1210/clinem/dgad465
The paper
Melin, J., Forslund, M., Alesi, S., Piltonen, T., Romualdi, D., Spritzer, P. M., Tay, C. T., Pena, A., Witchel, S. F., Mousa, A., & Teede, H. (2024). Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad465

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.